COPD Exacerbation Follow Up

Impact of an AI Tool on COPD Exacerbation Outcomes

Recruiting
40 years or above
All
Phase N/A
485 participants needed
2 Locations

Study Overview

The goal of this study is to evaluate the impact of implementing an AI-enabled clinical workflow tool (Viz COPD) on respiratory specialist follow up and clinical outcomes after an acute exacerbation.

Study Details

Time perspective: This study will collect data prospectively for the Experimental cohort and retrospectively for the Control cohort. There is also an Exploratory cohort which will collect retrospective and prospective data.

Eligibility Criteria

You may be eligible for this study if you meet the following criteria:

  • Conditions: COPD (Chronic Obstructive Pulmonary Disease)
  • Age: 40 years or above
  • Gender: All

Inclusion Criteria:

  • Patients aged 40 years or older at the time of arrival to the emergency department.
  • Patients with a clinical diagnosis of COPD who present to the emergency department for a moderate or severe COPD exacerbation.
  • A moderate exacerbation is defined as an acute exacerbation requiring either systemic corticosteroids (such as intramuscular, intravenous or oral) and/or antibiotics.
  • A severe exacerbation is defined as an acute exacerbation requiring hospitalization, or observation for >24 hours in emergency department/urgent care facility or resulting in death.
  • Patients on dual (LABA/LAMA, LABA/ICS, LAMA/ICS) or triple (LABA/LAMA/ICS) long-acting bronchodilator inhalers.

Exclusion Criteria:

  • Patients on bronchodilator inhaler monotherapy.
  • Patients leaving against medical advice or expiring during hospitalization.
  • Patients with tracheostomy.
  • Patients with advanced cancer.
  • Patients who have received a lung transplant.
  • Discharge to hospice care.
  • Transfer to another hospital.

This study investigates COPD exacerbation. It looks at how an AI-enabled clinical workflow tool can affect follow-up care and outcomes for patients after an acute exacerbation.

The study evaluates the use of this tool to see if it improves respiratory specialist follow-up and clinical outcomes. It does not focus on how the study is set up or the specific methods used.

  • Who can participate: Adults aged 40 or older with a clinical diagnosis of COPD who visit the emergency department for a moderate or severe exacerbation are eligible. Exclusion criteria include use of bronchodilator inhaler monotherapy, advanced cancer, or a tracheostomy.
  • Study details: Participants will use an AI-enabled clinical workflow tool during the study. A placebo is not used in this study.
Updated on 02 Jun 2026. Study ID: NCT07118306

Find a study site near you

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
United States Only: Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language